Biologics CDMO Packaging Market Poised for 8.7% Growth by 2030

The biologics CDMO (contract development and manufacturing organization) secondary packaging market is projected to reach USD 3,622.6 million by 2030, growing at a compound annual rate of 8.7%. This growth is primarily driven by rising drug production, the expanding pharmaceutical industry, and the increasing prevalence of various diseases, including chronic conditions, infectious diseases, and genetic disorders.

In 2021, boxes dominated the market with a revenue of approximately USD 1 billion, and they are expected to maintain this leadership position in the coming years. These boxes are specifically designed for transporting biological products, such as frozen and temperature-sensitive biologics, offering an ideal combination of temperature control and payload capacity. Moreover, they meet the highest standards for biological drug packaging, with custom-engineered solutions that ensure both superior quality and environmental responsibility.

Blister packs accounted for around 40% of the market share in 2021 and are set to experience the fastest growth moving forward. This is attributed to their strong presence as a preferred packaging option, with many CDMOs offering secondary packaging services for biologics. Blister packaging is well-suited for biologics due to its transparency and adaptability, making it a practical solution for the sensitive nature of these drugs. Additionally, manufacturers are increasingly shifting toward monodose packaging solutions, driving rapid growth in this segment.

Download free report sample at: https://www.psmarketresearch.com/market-analysis/biologics-cdmo-secondary-packaging-market/report-sample

North America led the market with over 40% revenue share, thanks to the rising outsourcing of drug R&D and production by major biopharmaceutical companies. Many businesses seek to collaborate with specialized packaging providers that offer innovative, non-traditional solutions while maintaining cost and time efficiency.

Meanwhile, the Asia-Pacific (APAC) region is expected to witness the fastest growth in the years ahead. This is fueled by the rising prevalence of chronic diseases, the increasing focus on contract manufacturing, and key players investing in facility expansions across the region. Europe’s growth will be more moderate, driven by the rising demand for biologic products, such as vaccines, which are pushing pharmaceutical companies to increase their R&D expenditures.

The growing global drug production is propelling the demand for biologics CDMO secondary packaging, a trend that is expected to continue over the coming years.

About P&S Intelligence

 

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.

 

Contact:
Chandra Mohan
AVP – Business Development
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com